Table 1.
Characteristics of RSLE, SLE patients and control subjects
| RSLE | SLE | NC | |
|---|---|---|---|
| Number | 35 | 37 | 28 |
| Sex (female/male) | 34/1 | 37/0 | 27/1 |
| Age, year (mean ± s.d., range) | 39·1 ± 10·1 | 39·3 ± 10·8 | 38·5 ± 7·9 |
| (20–59) | (20–67) | (22–51) | |
| SLEDAI score (mean ± s.d., range) | 7·9 ± 5·9 | 2·8 ± 5·6 | n.a. |
| (0–20) | (0–32) | ||
| Duration of diagnosis, years (mean ± s.d., range) | 12·4 ± 6·3 | 9·0 ± 6·8 | n.a. |
| (1·7–26·6) | (0·3–25·6) | ||
| Serum creatinine, µmol/l (mean ± s.d., range) | 105·2 ± 73·0* | 68·2 ± 11·7 | n.d. |
| (45·0–336·0) | (46·0–92·0) | ||
| Serum urea, mmol/l (mean ± s.d., range) | 8·5 ± 5·7** | 4·7 ± 1·3 | n.d. |
| (3·0–26·0) | (2·3–7·3) | ||
| Treatment with prednisolone | |||
| Patient no. (%) | 35 (100·0) | 19 (51·4) | n.a. |
| Daily dose, mg | 6·7 ± 5·1 | 3·2 ± 6·6 | |
| Treatment with hydroxychloroquine | |||
| Patient no. (%) | 14 (40·0) | 23 (62·2) | n.a. |
| Daily dose, mg | 87·5 ± 99·0 | 112·0 ± 108·0 | |
| Treatment with azathioprine | |||
| Patient no. (%) | 13 (37·1) | 5 (13·5) | n.a. |
| Daily dose, mg | 20·0 ± 30·0 | 9·0 ± 30·0 | |
| Treatment with cyclosporin A | |||
| Patient no. (%) | 9 (25·7) | 0 (0·0) | n.a. |
| Daily dose, mg | 20·9 ± 43·5 | 0 | |
n.a. = not applicable; n.d. = not determined.
*
P < 0·05
**
P < 0·0001 compared with SLE patients (Mann–Whitney rank sum test).